

Tamas Masszi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8293072/publications.pdf>

Version: 2024-02-01

58
papers

8,652
citations

147801

31
h-index

128289

60
g-index

60
all docs

60
docs citations

60
times ranked

7683
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	27.0	1,246
2	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	27.0	1,144
3	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861
4	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	10.7	723
5	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. <i>New England Journal of Medicine</i> , 2015, 372, 426-435.	27.0	720
6	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1853-1862.	13.7	633
7	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	1.6	394
8	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. <i>JAMA Oncology</i> , 2015, 1, 643.	7.1	362
9	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
10	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2475-2482.	1.6	185
11	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	13.7	177
12	Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. <i>Blood</i> , 2018, 132, 2639-2642.	1.4	172
13	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	3.5	140
14	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 945-954.	2.5	124
15	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
16	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , the, 2020, 7, e226-e237.	4.6	93
17	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	1.4	90
18	Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 663187.	4.8	87

#	ARTICLE	IF	CITATIONS
19	Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. <i>Haematologica</i> , 2014, 99, 1184-1190.	3.5	83
20	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
21	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 247-255.	1.6	69
22	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	2.5	58
23	Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 1252-1257.	1.6	57
24	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	1.6	53
25	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	3.5	48
26	Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. <i>European Journal of Haematology</i> , 2016, 97, 192-200.	2.2	46
27	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.5	45
28	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. <i>Leukemia</i> , 2021, 35, 1344-1355.	7.2	43
29	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	4.1	41
30	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate- or high-risk myelofibrosis. <i>British Journal of Haematology</i> , 2021, 195, 244-248.	2.5	37
31	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33
32	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	17.0	32
33	Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. <i>Leukemia and Lymphoma</i> , 2012, 53, 907-914.	1.3	30
34	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1028-1035.	1.3	30
35	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 860-867.	2.5	30
36	Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2015, 56, 120-127.	1.3	28

#	ARTICLE	IF	CITATIONS
37	Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients. <i>Acta Haematologica</i> , 2012, 127, 34-42.	1.4	27
38	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. <i>British Journal of Haematology</i> , 2015, 171, 344-354.	2.5	26
39	Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. <i>International Journal of Hematology</i> , 2019, 110, 559-565.	1.6	25
40	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. <i>Annals of Hematology</i> , 2018, 97, 617-627.	1.8	23
41	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e403-e414.	4.6	23
42	Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common <i>TERT</i> Polymorphism rs2736100. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 98-104.	2.5	21
43	Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse. <i>Blood</i> , 2015, 126, 3172-3172.	1.4	20
44	Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. <i>Leukemia Research</i> , 2018, 65, 42-48.	0.8	19
45	Medium-sized <i>FLT3</i> internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. <i>Leukemia and Lymphoma</i> , 2014, 55, 1510-1517.	1.3	18
46	The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1613-1618.	3.5	17
47	Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR). <i>Blood</i> , 2014, 124, 4547-4547.	1.4	17
48	Remarkably Reduced Transplant-Related Complications by Dibromomannitol Non-Myeloablative Conditioning before Allogeneic Bone Marrow Transplantation in Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2001, 105, 64-70.	1.4	14
49	Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients. <i>Biomarkers in Medicine</i> , 2022, 16, 317-330.	1.4	13
50	<i>HFE</i> C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 929-934.	2.5	11
51	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. <i>British Journal of Haematology</i> , 2021, 193, 561-569.	2.5	10
52	Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers. <i>Pathology and Oncology Research</i> , 2022, 28, 1610276.	1.9	9
53	<i>c-MYC</i> expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide+dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	2.2	8
54	Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 391-398.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms. <i>Pathology</i> , 2019, 51, 301-307.	0.6	7
56	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. <i>British Journal of Haematology</i> , 2018, 182, 279-284.	2.5	3
57	Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers. <i>Pathology and Oncology Research</i> , 2021, 27, 613264.	1.9	2
58	Investigation of TGFBI $\hat{\sim}$ 1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 215-223.	2.4	1